



PRESS RELEASE

Cipla appoints Dr. Peter Mugenyi as an Independent Director on the Board

India, Mumbai, 12th February, 2014: Cipla, a global pharmaceutical company is delighted to announce the appointment of Dr. Peter Mugenyi as an independent director on the Board with immediate effect. Dr. Mugenyi is the Director and Co-Founder of the Joint Clinical Research Centre (JCRC) based in Kampala. He is highly regarded globally for his leadership in helping Africa battle its mounting AIDS epidemic. A pediatrician by training, Dr. Peter Mugenyi is recognized as one of the worlds' foremost specialists and researchers in the field of HIV/AIDS.

Announcing the appointment, **Dr. Y K Hamied, Chairman, Cipla Limited** said: "It is a privilege for Cipla to have Dr. Mugenyi as a member of Cipla's board of directors. His presence would be most influential in the heart of the highest governing body of Cipla. I believe that as a world leader, Dr. Mugenyi will be a source of inspiration for us, someone who can also guide us in our journey towards our vision of 'None shall be denied'."

Dr. Peter Mugenyi said: "I am proud to be part of Cipla's contribution to humanity and would like to emphasize that innovation in the crucial area of human survival should not be entirely dependent on revenue generation. It should primarily aim at alleviating the human suffering and saving lives. This does not contradict fair trade, because business success and humanism are not incompatible." He also added, "Establishing the earnest partnership between doctors and the pharmaceutical drug industry would help make critical life-saving drugs accessible to all in need."

Dr. Peter Mugenyi is the author of *Genocide by Denial: How Profiteering from HIV/AIDS Killed Millions*. Published in 2008, a book that details the story of how Western Governments and drug companies callously oversaw the death of millions of Africans who were unable to afford their branded drugs. A follow-up of this book was published in 2013. Dr. Mugenyi played a major consultative role in the formulation of the PEPFAR (President's Emergency Plan for AIDS relief) program, which was announced in the 2003 State of the Union address by President George W. Bush. PEPFAR has since put millions of Africans on lifesaving anti-retroviral treatment.

About Cipla

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in 2012-13 was 1.5 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognized globally for the pioneering role

played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla's research and development focuses on developing innovative products and drug delivery systems and has given India and the world many 'firsts' for instance Triomune. In a tightly regulated environment, the company's manufacturing facilities have approvals from all the main regulators including USFDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard domestically and internationally.

Media Contact:

Charlotte Chunawala
Corporate Communications
Mob: +91 7506257377
Email: charlotte.chunawala@cipla.com

Jaisingh Balakrishnan
Corporate Communications
Mob: +91 9833836185
Email: jaisingh.krishnan@cipla.com